NCT05722951CompletedPhase 3
Metformin Efficacy and Safety in Epileptic Patients
Source: ClinicalTrials.gov · Last updated 2 Dec 2024
Brief summary (registry, in English)
The goal of this clinical trial is to Evaluating Metformin Efficacy and Safety when Co-administered with Antiepileptic Drugs in Patients with Seizures. The main question it aims to answer is: * Does metformin have beneficial effect on epileptic patients? * How metformin can affect epileptic patient's health? Participants will be divided into 2 groups (control group and treatment group) * Control group will receive standard treatment (levetiracetam \&/or sodium valproate). * Treatment group will receive standard treatment (levetiracetam \&/or sodium valproate) + metformin
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 60 (actual)
- First submitted
- 1 Feb 2023
- Start date
- Oct 2022
- Primary completion date
- Jun 2024
- Lead sponsor
- Tanta University
- Diseases
- Epilepsy
- NCT number
- NCT05722951
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 60
- From Oct 2022 to the primary completion date, Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients having acute or chronic disease which may cause tissue hypoxia and increase the risk of lactic acidosis (e.g. cardiac/respiratory failure, recent myocardial infarction).
- Cancer patients.
- Patients with known hypersensitivity to the drug.
Lab values
- Patients with severe liver damage or kidney disease (eGFR below 45mL/min/1.73 m²).
Other
- Patients who are already taking metformin.
- Pregnant or lactating women.
Who the study is looking for
- Age: 18 - 65 years old
- Obese and overweight patients with body mass index (BMI) ≥ 25.
- Diabetic \& non diabetic patients.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Omnia Ashraf Abd El Aziz Ahmed Kotb Coordinator of this site? Confirm its status | Alexandria | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.